Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,769.00
Bid: 1,768.50
Ask: 1,769.50
Change: 8.00 (0.45%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,772.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brexit tussle bogs down UK midcaps

Wed, 23rd Oct 2019 09:15

* FTSE 250 down 0.4%, FTSE 100 up 0.2%

* Fresnillo at bottom of main index after weak outlook

* Exporters benefit from weaker pound
(Adds company news items, updates share moves)

By Muvija M and Shashwat Awasthi

Oct 23 (Reuters) - Shares in domestically-focussed UK
companies slid on Wednesday while those on the blue-chip FTSE
100 inched higher as votes in parliament kept investors guessing
on the final timing and shape of Britain's withdrawal from the
European Union.

With worries over turbulence in Hong Kong and global growth
feeding losses for stock markets globally, the FTSE 250 index of
midcap firms dipped 0.4% by 0745 GMT.

Helped by a dip for the pound in response to Prime
Minister Boris Johnson's failure to get MPs to back his
accelerated Brexit timetable overnight, the exporter-heavy FTSE
100 edged 0.2% higher.

Precious metals miner Fresnillo dropped nearly 2%
after it forecast annual silver and gold production at the lower
end of an already reduced target range, and reported a fall in
quarterly output.

While lawmakers voted for a second hearing on the departure
agreement, rejection of Johnson's timetable raises the
likelihood of another delay in Britain's withdrawal as well as
the prospect of a snap election before Christmas.

"The latest twist in the Brexit saga also means that
investors may have to contend with more political risk by way of
a UK election," said Han Tan, Market Analyst at FXTM.

Raymond James analyst Chris Bailey called the Brexit
situation "a mess" overall and said the core scenario of an
extension or an election was becoming more likely.

The uncertainty around Brexit and its consequences continues
to show up in the performance of UK firms. Housebuilders
, considered among the most vulnerable, lost nearly
1%, with Barratt, Persimmon and Berkeley
the biggest losers on the blue chip index.

That was offset by gains for companies who earn largely in
foreign currencies including British American Tobacco
and pharmaceutical giant GlaxoSmithKline.

Miner Centamin also shone on the FTSE 250 with a 3%
gain after third-quarter production report.
(Reporting by Muvija M and Shashwat Awasthi in Bengaluru;
Editing by Shounak Dasgupta and Patrick Graham)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.